Zeke Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,798
| Closed | -$297K | – | 521 |
|
|
2022
Q3 | $297K | Sell |
2,798
-398
| -12% | -$42.2K | 0.02% | 314 |
|
|
2022
Q2 | $312K | Sell |
3,196
-886
| -22% | -$86.5K | 0.02% | 312 |
|
|
2022
Q1 | $383K | Sell |
4,082
-223
| -5% | -$20.9K | 0.02% | 293 |
|
|
2021
Q4 | $367K | Buy |
4,305
+297
| +7% | +$25.3K | 0.02% | 201 |
|
|
2021
Q3 | $384K | Buy |
4,008
+542
| +16% | +$51.9K | 0.02% | 177 |
|
|
2021
Q2 | $337K | Buy |
3,466
+489
| +16% | +$47.5K | 0.02% | 190 |
|
|
2021
Q1 | $290K | Buy |
2,977
+324
| +12% | +$31.6K | 0.02% | 208 |
|
|
2020
Q4 | $254K | Buy |
+2,653
| New | +$254K | 0.02% | 218 |
|
|
2020
Q3 | – | Sell |
-1,918
| Closed | -$234K | – | 249 |
|
|
2020
Q2 | $234K | Buy |
+1,918
| New | +$234K | 0.05% | 168 |
|
|
2019
Q2 | – | Sell |
-8,495
| Closed | -$748K | – | 576 |
|
|
2019
Q1 | $748K | Buy |
8,495
+2,605
| +44% | +$229K | 0.07% | 252 |
|
|
2018
Q4 | $421K | Buy |
+5,890
| New | +$421K | 0.04% | 370 |
|